Arch Therapeutics (Arch Therapeutics) Cash-to-Debt : 0.03 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Arch Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.03.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Arch Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Arch Therapeutics's Cash-to-Debt or its related term are showing as below:

ARTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 2.56 Max: No Debt
Current: 0.03

During the past 13 years, Arch Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 2.56.

ARTH's Cash-to-Debt is ranked worse than
97.21% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs ARTH: 0.03

Arch Therapeutics Cash-to-Debt Historical Data

The historical data trend for Arch Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Arch Therapeutics Cash-to-Debt Chart

Arch Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.32

1.42

0.22

0.04

Arch Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															-	0.02	0.03	0.04	0.03

Competitive Comparison of Arch Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Arch Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Cash-to-Debt falls into.

Arch Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Arch Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.223	/	(5.628	+	0)
	=	0.04

Arch Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.206	/	(7.143	+	0)
	=	0.03

Arch Therapeutics (OTCPK:ARTH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Arch Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Therapeutics (Arch Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

235 Walnut Street, Suite 6, Framingham, MA, USA, 01702

Website

https://www.archtherapeutics.com

Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.

Executives

Terrence W Norchi	director, officer: President & CEO	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams	officer: CFO and Treasurer	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen	officer: Vice President, Sales	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat	director
Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis	officer: CFO & Treasurer
Avtar S Dhillon	director	C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal	director	100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber	officer: Chief Financial Officer	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter	officer: Chief Operating Officer	C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616